

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-24. (Canceled)

25. (Previously presented) A method for the treatment of insulin dependent (type I) diabetes comprising administering to a prediabetic mammal, or a mammal having partial  $\beta$  cell destruction, a composition comprising a soluble fibronectin polypeptide comprising an EILDV (SEQ ID NO:19) motif, in an amount effective to treat diabetes.

26-30. (Canceled)

31. (Previously presented) The method according to claim 25, wherein the fibronectin polypeptide is a component of a chimeric molecule.

32. (Previously presented) The method according to claim 31, wherein the chimeric molecule further comprises a toxin moiety.

33. (Previously presented) The method according to claim 25, wherein the mammal is prediabetic.

34. (Previously presented) The method according to claim 33, wherein the prediabetic mammal is a human.

35. (Previously presented) The method according to claim 25, wherein the mammal has partial  $\beta$  cell destruction.

36. (Canceled)